NASDAQ:NAKA · NASDAQ Global Market
+$0.00 today
Vol 0.22M · Avg 0.24M
Cash Flow
Check whether earnings turn into cash
Use operating cash flow, capital spending, free cash flow, and financing activity to see how much value is left for reinvestment or owners.
Free Cash Flow
Net Income to FCF bridge
Analysis
Analysis will appear once cash flow data is available for this period.
Operating Cash Flow
—
Investing Cash Flow
—
Financing Cash Flow
—
Cash Flow Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -$52.2M -1343.7% | -$3.6M -123.7% | -$1.6M +36.3% | -$2.5M -1801.3% | $149.3K | $487.6M | $476.4M | $465.2M |
| Depreciation & Amortization | $242.0K +9.8% | $220.3K +8.4% | $203.2K +66.6% | $122.0K +92.4% | $63.4K | $374.2M | $1.2B | $631.8M |
| Deferred Income Tax | $0 | $0 | $0 | $0 | $0 | $1.4B | -$1.5B | $304.2M |
| Stock-Based Compensation | $2.4M +879.2% | $240.9K -41.9% | $414.7K -81.3% | $2.2M | $0 | $489.0M | $354.6M | -$1.6B |
| Change in Working Capital | -$4.1M -1242.6% | -$302.0K -359.5% | $116.4K +250.2% | $33.2K +136.4% | -$91.3K | $350.4M | -$1.6B | $1.5B |
| Accounts Receivables | $0 +100.0% | -$41.0K -158.0% | -$15.9K -122.9% | -$7.1K -1876.3% | $401 | $592.6M | $1.3B | $626.2M |
| Inventory | $0 -100.0% | $58.9K +532.0% | -$13.6K -233.6% | $10.2K +133.3% | -$30.6K | $1.0B | $1.2B | $1.1B |
| Accounts Payables | -$2.0M -32010.7% | -$6.1K -103.7% | $163.6K +33.7% | $122.3K | $0 | $948.2M | -$1.5B | $433.0M |
| Other Working Capital | -$2.1M -569.3% | -$313.8K -1675.2% | -$17.7K +80.8% | -$92.2K -51.0% | -$61.1K | $567.4M | $1.3B | $601.0M |
| Other Non-Cash Items | $30.2M +7747.2% | $384.5K -11.4% | $433.7K +1414.9% | $28.6K +2862800.0% | $1 | $1.4B | -$1.5B | $300.0M |
| Operating Cash Flow | -$23.5M -664.9% | -$3.1M -583.9% | -$449.5K -220.2% | -$140.4K -215.6% | $121.4K | $7.2B | $8.9B | $10.5B |
| Capital Expenditures | -$234.4K +41.6% | -$401.6K -2685.2% | -$14.4K +95.5% | -$317.4K -399.0% | -$63.6K | $664.0M | $1.4B | $697.6M |
| Acquisitions (Net) | -$29.8M | $0 | $0 | $0 | $0 | $937.0M | $1.1B | $1.3B |
| Purchases of Investments | $0 | $0 | $0 | $0 | $0 | $444.2M | $1.4B | $1.3B |
| Sales of Investments | $5.1M | $0 | $0 | $0 | $0 | $822.2M | $318.2M | -$1.5B |
| Other Investing Activities | -$655.0M -168573.3% | -$388.3K | $0 | $0 | $0 | $616.4M | $370.0M | $1.2B |
| Investing Cash Flow | -$680.0M -169215.7% | -$401.6K -2685.2% | -$14.4K +95.5% | -$317.4K -399.0% | -$63.6K | $4.8B | $6.4B | $5.1B |
| Debt Repayment | $191.2M +31198.0% | -$614.9K -176.6% | $802.5K +435.0% | $150.0K +416.9% | -$47.3K | $680.8M | $759.2M | $1.1B |
| Common Stock Issued | $523.7M +8836.6% | $5.9M | $0 -100.0% | $400.0K +19900.0% | $2.0K | $778.8M | $946.8M | $812.4M |
| Common Stock Repurchased | -$320.4K -1346.8% | -$22.1K | $0 | $0 | $0 | $351.8M | -$1.6B | $1.5B |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $535.2M | $613.6M | $692.0M |
| Other Financing Activities | $9.2M | $0 | $0 | $0 | $0 | -$1.6B | $1.3B | $1.1B |
| Financing Cash Flow | $723.8M +13757.1% | $5.2M +550.9% | $802.5K +45.9% | $550.0K +1313.0% | -$45.3K | $12.2B | $13.9B | -$15.5B |
| Effect of Forex Changes | $0 | $0 | $0 | $0 -100.0% | $82.2K | $1.3B | $1.1B | $990.2M |
| Net Change in Cash | $20.3M +1061.8% | $1.7M +416.3% | $338.6K +267.1% | $92.2K -2.6% | $94.7K | $3.2B | $4.9B | $6.5B |
| Free Cash Flow | -$23.7M -583.2% | -$3.5M -649.2% | -$463.9K -1.3% | -$457.8K -891.4% | $57.8K | $8.6B | -$16.8B | $11.1B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Agilon Health, Inc.
NYSE:AGL
$1.85B
Delcath Systems, Inc.
NASDAQ:DCTH
$455.69M
DBV Technologies S.A.
NASDAQ:DBVT
$378.44M
Simulations Plus, Inc.
NASDAQ:SLP
$371.58M
SOPHiA GENETICS S.A.
NASDAQ:SOPH
$367.75M
Amarin Corporation plc
NASDAQ:AMRN
$338.58M
Cellectis S.A.
NASDAQ:CLLS
$331.38M
Lyell Immunopharma, Inc.
NASDAQ:LYEL
$327.84M
Larimar Therapeutics, Inc.
NASDAQ:LRMR
$278.98M
Definitive Healthcare Corp.
NASDAQ:DH
$82.28M
SEC Filings
Recent regulatory filings
No filings found.
Does NAKA generate free cash flow?
Nakamoto Inc. (NAKA) generated -$23.75M of free cash flow in fiscal 2025.
How much operating cash flow does NAKA produce?
Operating cash flow was -$23.51M, before capital expenditures of $234,383.00.
Explore More
Continue the stock analysis
Jump to another research area for this company.